| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18559769 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 109 journal articles in the PubMed database | Email to a friend | | |
| Hong DS, Reddy SB, Prieto VG, et al.
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. [Case Reports, Journal Article, Research Support, N.I.H., Extramural]
Arch Dermatol 2008 Jun; 144(6):779-82.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Kong HH, Sibaud V, Chanco Turner ML, et al.
Sorafenib-induced eruptive melanocytic lesions. [Case Reports, Letter]
Arch Dermatol 2008 Jun; 144(6):820-2.
Full Citation | Publisher Full Text | Find Related Articles | | Lountzis NI, Maroon MS
Sorafenib-induced palmoplantar hyperkeratosis. [Journal Article]
J Drugs Dermatol 2008 Jun; 7(6):588-9.
Abstract | Full Citation | Find Related Articles | | Flaherty KT
Sorafenib: delivering a targeted drug to the right targets. [Journal Article]
Expert Rev Anticancer Ther 2007 May; 7(5):617-26.
Abstract | Full Citation | Find Related Articles | | Kasibhatla M, Steinberg P, Meyer J, et al.
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. [Journal Article]
Clin Genitourin Cancer 2007 Mar; 5(4):291-4.
Abstract | Full Citation | Find Related Articles | | Strumberg D
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. [Journal Article]
Drugs Today (Barc) 2005 Dec; 41(12):773-84.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ratain MJ, Eisen T, Stadler WM, et al.
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. [Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial]
J Clin Oncol 2006 Jun 1; 24(16):2505-12.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Grandinetti CA, Goldspiel BR
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. [Journal Article]
Pharmacotherapy 2007 Aug; 27(8):1125-44.
Abstract | Full Citation | | Autier J, Escudier B, Wechsler J, et al.
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. [Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't]
Arch Dermatol 2008 Jul; 144(7):886-92.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
